Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $36.
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $36.